Valette H[au] - Search Results

Year	Number of Results
1974	1
1975	1
1977	2
1979	2
1980	2
1981	2
1982	2
1983	2
1984	2
1985	1
1986	1
1987	3
1988	6
1990	4
1991	3
1992	4
1993	5
1994	4
1995	5
1996	3
1997	3
1998	1
1999	5
2000	1
2001	2
2002	4
2003	6
2004	1
2005	5
2006	6
2007	3
2008	1
2009	4
2010	3
2011	3
2012	4
2013	3
2015	2
2016	1
2023	0

1

Beta-blocking agent for treatment of infantile hemangioma.

Bigorre M, Van Kien AK, Valette H. Bigorre M, et al. Among authors: valette h. Plast Reconstr Surg. 2009 Jun;123(6):195e-196e. doi: 10.1097/PRS.0b013e3181a3f435. Plast Reconstr Surg. 2009. PMID: 19483538 No abstract available.

2

Type II hyperprolinaemia with renal involvement.

Bellet H, Morin D, Daudet H, Dumas ML, Valette H, Magnan de Bornier B, Dumas R. Bellet H, et al. Among authors: valette h. J Inherit Metab Dis. 1991;14(5):846-7. doi: 10.1007/BF01799968. J Inherit Metab Dis. 1991. PMID: 1779641 No abstract available.

3

Haemodynamic effects of diltiazem in healthy volunteers.

Valette H, Apoil E. Valette H, et al. Br J Clin Pharmacol. 1980 Dec;10(6):623-4. doi: 10.1111/j.1365-2125.1980.tb00522.x. Br J Clin Pharmacol. 1980. PMID: 7470375 Free PMC article. Clinical Trial. No abstract available.

4

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.

Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Grégoire MC, Coulon C, Valette H, Dollé F, Ribeiro MJ, Hantraye P, Remy P. Kas A, et al. Among authors: valette h. J Cereb Blood Flow Metab. 2009 Sep;29(9):1601-8. doi: 10.1038/jcbfm.2009.74. Epub 2009 Jun 3. J Cereb Blood Flow Metab. 2009. PMID: 19491921

5

Preparation and pharmacological characterization of [76Br]-meta-bromobenzylguanidine ([76Br]MBBG).

Loc'h C, Mardon K, Valette H, Brutesco C, Merlet P, Syrota A, Maziere B. Loc'h C, et al. Among authors: valette h. Nucl Med Biol. 1994 Jan;21(1):49-55. doi: 10.1016/0969-8051(94)90128-7. Nucl Med Biol. 1994. PMID: 9234263

6

Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand.

Peyronneau MA, Saba W, Goutal S, Damont A, Dollé F, Kassiou M, Bottlaender M, Valette H. Peyronneau MA, et al. Among authors: valette h. Drug Metab Dispos. 2013 Jan;41(1):122-31. doi: 10.1124/dmd.112.046342. Epub 2012 Oct 12. Drug Metab Dispos. 2013. PMID: 23065531

7

Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C]methyl triflate.

Thominiaux C, Dollé F, James ML, Bramoullé Y, Boutin H, Besret L, Grégoire MC, Valette H, Bottlaender M, Tavitian B, Hantraye P, Selleri S, Kassiou M. Thominiaux C, et al. Among authors: valette h. Appl Radiat Isot. 2006 May;64(5):570-3. doi: 10.1016/j.apradiso.2005.12.003. Epub 2006 Jan 20. Appl Radiat Isot. 2006. PMID: 16427784

8

[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.

Saba W, Valette H, Schöllhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M. Saba W, et al. Among authors: valette h. Synapse. 2007 Jan;61(1):17-23. doi: 10.1002/syn.20337. Synapse. 2007. PMID: 17068778

9

Down-regulation of cardiac muscarinic receptors induced by di-isopropylfluorophosphate.

Valette H, Syrota A, Fuseau C. Valette H, et al. J Nucl Med. 1997 Sep;38(9):1430-3. J Nucl Med. 1997. PMID: 9293803 Free article.

10

Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo.

Valette H, Bottlaender M, Dollé F, Guenther I, Coulon C, Hinnen F, Fuseau C, Ottaviani M, Crouzel C. Valette H, et al. Life Sci. 1999;64(5):PL93-7. doi: 10.1016/s0024-3205(98)00573-6. Life Sci. 1999. PMID: 10072197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results